Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of PF-06751979 in Healthy Adults and Elderly
NCT02793232Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jun 2016
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-06751979 in Alzheimer's disease (AD) (3 arms), sponsored by Pfizer. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), Number of Participants With Abnormal Physical Examinations Findings and 6 more. Started Jun 2016; status: completed.
02
Drugs
PF-06751979
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02793232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02793232.